TY - JOUR T1 - The Public Health Impact of Delaying a Second Dose of the BNT162b2 or mRNA-1273 COVID-19 Vaccine JF - medRxiv DO - 10.1101/2021.02.23.21252299 SP - 2021.02.23.21252299 AU - Santiago Romero-Brufau AU - Ayush Chopra AU - Alex J Ryu AU - Esma Gel AU - Ramesh Raskar AU - Walter Kremers AU - Karen Anderson AU - Jayakumar Subramanian AU - Balaji Krishnamurthy AU - Abhishek Singh AU - Kalyan Pasupathy AU - Yue Dong AU - John C O’Horo AU - Walter R Wilson AU - Oscar Mitchell AU - Thomas C Kingsley Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/26/2021.02.23.21252299.abstract N2 - Objectives To estimate population health outcomes under delayedsecond dose versus standard schedule SARS-CoV-2 mRNA vaccination.Design Agent-based modeling on a simulated population of 100,000 based on a real-world US county. The simulation runs were replicated 10 times. To test the robustness of these findings, simulations were performed under different estimates for single-dose efficacy and vaccine administration rates, and under the possibility that a vaccine prevents only symptoms but not asymptomatic spread.Setting population level simulation.Participants 100,000 agents are included in the simulation, with a representative distribution of demographics and occupations. Networks of contacts are established to simulate potentially infectious interactions though occupation, household, and random interactionsInterventions we simulate standard Covid-19 vaccination, versus delayed-second-dose vaccination prioritizing first dose. Sensitivity analyses include first-dose vaccine efficacy of 70%, 80% and 90% after day 12 post-vaccination; vaccination rate of 0.1%, 0.3%, and 1% of population per day; assuming the vaccine prevents only symptoms but not asymptomatic spread; and an alternative vaccination strategy that implements delayed-second-dose only for those under 65 years of age.Main outcome measures cumulative Covid-19 mortality over 180 days, cumulative infections and hospitalizations.Results Over all simulation replications, the median cumulative mortality per 100,000 for standard versus delayed second dose was 226 vs 179; 233 vs 207; and 235 vs 236; for 90%, 80% and 70% first-dose efficacy, respectively. The delayed-second-dose strategy was optimal for vaccine efficacies at or above 80%, and vaccination rates at or below 0.3% population per day, both under sterilizing and non-sterilizing vaccine assumptions, resulting in absolute cumulative mortality reductions between 26 and 47 per 100,000. The delayed-second-dose for those under 65 performed consistently well under all vaccination rates tested.Conclusions A delayed-second-dose vaccination strategy, at least for those under 65, could result in reduced cumulative mortality under certain conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll research was supported with volunteer time and internal funds from our respective research institutions: MIT, ASU and Mayo Clinic. No third-party funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mayo Clinic Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code used will be available in our GitHub repository. https://github.com/ayushchopra96/deepabm-covid.git​ ER -